Prognostic Value of CD318 in AML at Assiut University Hospital.
NCT04708444 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2021-01-22
Summary
We will focus on the prognostic value of CD318 in acute myeloid leukemia patients at Assiut University Hospital
Conditions
Interventions
- DIAGNOSTIC_TEST
-
CD318
Flowcytometric marker
Sponsors & Collaborators
-
Shimaa Arafa Ibrahim
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-31
- Primary Completion
- 2022-09-30
- Completion
- 2023-03-31
More Related Trials
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788 ·Status: RECRUITING ·Phase: PHASE1
-
Assesment of JL1 Expression in Acute Leukemia
NCT04554381 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05241106 ·Status: RECRUITING ·Phase: PHASE2
-
Molecular Diagnostic Platform for AML
NCT04446741 ·Status: UNKNOWN
-
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
NCT00079482 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
NCT03298516 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
NCT01254188 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
NCT00373373 ·Status: COMPLETED ·Phase: PHASE2
-
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
NCT01066494 ·Status: UNKNOWN ·Phase: PHASE2
-
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01138306 ·Status: COMPLETED
-
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750 ·Status: RECRUITING ·Phase: PHASE1
-
Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
NCT03283228 ·Status: UNKNOWN
-
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
NCT02984995 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL
NCT00384228 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL
NCT02848911 ·Status: TERMINATED ·Phase: PHASE1
-
Drug-screening in AML at Relapse for Targeted Treatment
NCT05732688 ·Status: COMPLETED ·Phase: NA
-
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
NCT04827069 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
NCT00462761 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Study of Quizartinib
NCT02675478 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05241093 ·Status: RECRUITING ·Phase: PHASE2
-
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT03541369 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572 ·Status: RECRUITING ·Phase: PHASE1
-
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers in Young Patients With Acute Myeloid Leukemia
NCT01138332 ·Status: COMPLETED